What are the ADA (American Diabetes Association) 2025 guidelines for managing type 2 diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 2, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The American Diabetes Association 2025 guidelines for managing type 2 diabetes recommend a comprehensive approach to cardiovascular risk reduction, including the use of SGLT2 inhibitors or GLP-1 receptor agonists for patients with established cardiovascular disease, heart failure, or chronic kidney disease, due to their proven benefits in reducing morbidity and mortality 1.

Key Recommendations

  • The guidelines emphasize the importance of individualized glycemic targets, comprehensive cardiovascular risk reduction, and early combination therapy for patients with type 2 diabetes.
  • First-line pharmacological treatment typically includes metformin, along with lifestyle modifications such as medical nutrition therapy and at least 150 minutes of moderate-intensity physical activity per week.
  • For patients with established cardiovascular disease, heart failure, or chronic kidney disease, GLP-1 receptor agonists or SGLT-2 inhibitors are recommended regardless of HbA1c levels due to their proven cardiovascular and renal benefits 1.

Cardiovascular Risk Reduction

  • The guidelines highlight the importance of addressing cardiovascular risk factors, including hypertension, hyperlipidemia, and obesity, to improve long-term outcomes and reduce mortality in patients with type 2 diabetes.
  • SGLT2 inhibitors and GLP-1 receptor agonists have been shown to have beneficial effects on cardiovascular outcomes, including reduced risk of heart failure hospitalizations and major adverse cardiovascular events 1.

Monitoring and Follow-up

  • Regular monitoring includes quarterly HbA1c testing until targets are met, annual comprehensive foot exams, regular eye examinations, and screening for complications.
  • The guidelines recommend a patient-centered approach to diabetes management, with consideration of individual preferences, values, and goals.

Pharmacologic Approaches

  • The guidelines recommend reevaluating medication plans and medication-taking behavior at regular intervals (e.g., every 3-6 months) and adjusting as needed to incorporate specific factors that impact choice of treatment 1.
  • Early combination therapy can be considered in adults with type 2 diabetes at treatment initiation to shorten time to attainment of individualized treatment goals.

From the Research

ADA 2025 Guidelines for Managing Type 2 Diabetes

  • The American Diabetes Association (ADA) guidelines for 2025 are not directly mentioned in the provided studies, but we can infer some recommendations based on the latest research.
  • The studies suggest that GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are effective in managing type 2 diabetes and reducing cardiovascular risk 2, 3, 4, 5.
  • GLP-1 RAs are recommended as the preferred first injectable glucose-lowering therapy for type 2 diabetes, even before insulin treatment, due to their effectiveness in reducing HbA1c levels and body weight, as well as their cardiovascular benefits 2.
  • SGLT-2is are also recommended for their ability to reduce cardiovascular risk and kidney complications in patients with type 2 diabetes 3, 4, 5.
  • The combination of GLP-1 RAs and SGLT-2is may be considered for patients with type 2 diabetes who do not have contraindications, as it may provide additive cardioprotective benefits 3, 4.
  • Early combination therapy with SGLT-2is and GLP-1 RAs or dual GIP/GLP-1 RAs may be considered for patients with type 2 diabetes, as it may enhance efficacy in achieving target HbA1c levels and preventing complications 4.

Key Recommendations

  • GLP-1 RAs and SGLT-2is are recommended for managing type 2 diabetes and reducing cardiovascular risk.
  • Combination therapy with GLP-1 RAs and SGLT-2is may be considered for patients with type 2 diabetes.
  • Early combination therapy with SGLT-2is and GLP-1 RAs or dual GIP/GLP-1 RAs may be considered for patients with type 2 diabetes.

Cardiovascular Benefits

  • GLP-1 RAs and SGLT-2is have been shown to reduce cardiovascular risk in patients with type 2 diabetes 2, 3, 4, 5.
  • The combination of GLP-1 RAs and SGLT-2is may provide additive cardioprotective benefits 3, 4.
  • GLP-1 RAs may reduce the risk of stroke, while SGLT-2is may reduce the risk of hospitalization for heart failure 5.

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

If someone does not achieve adequate weight loss with Glucagon-like peptide (GLP) receptor agonists, can Glucose-dependent insulinotropic polypeptide (GIP) receptor agonists be tried?
What is the comparison between Glucagon-like peptide-1 (GLP-1) and Sodium-glucose cotransporter 2 (SGLT2) inhibitors?
What is the difference between Gastric Inhibitory Polypeptide (GIP) and Glucagon-Like Peptide (GLP)?
Is it okay to add glipizide (a sulfonylurea) 5 mg to a 48-year-old patient with type 2 diabetes on Lantus (insulin glargine) 23 units, 1:10 carb ratio, and Farxiga (dapagliflozin) 10 mg, who does not want to start mealtime insulin or GLP-1 receptor agonists?
What is the initial management for a 58-year-old patient with steroid-induced diabetes (SID)?
What is the treatment for a poison ivy rash near the eye?
What are the American Diabetes Association (ADA) 2025 guidelines for managing type 2 diabetes?
What are the diagnostic criteria for stage V Chronic Kidney Disease (CKD)?
What are alternative treatments to clindamycin (antibiotic) and oxacillin (antibiotic) for therapy failure?
What to do if an EKG (electrocardiogram) shows possible left atrial enlargement?
Is minocycline (Minocin) associated with a raise in troponin levels?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question